Nektar Therapeutics
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-164.1M | $-119.0M | $-276.1M | $-368.2M | $-523.8M | $-444.4M | $-440.7M | $681.3M |
| Depreciation & Amortization | $1.0M | $4.1M | $7.0M | $12.2M | $13.0M | $12.5M | $11.0M | $8.8M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — | — | — | — |
| Net Cash from Operating Activities | $-208.5M | $-175.7M | $-192.6M | $-304.0M | $-412.7M | $-313.3M | $-328.7M | $718.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $171.0K | $1.5M | $865.0K | $5.7M | $15.0M | $7.3M | $26.3M | $14.2M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-1.2M | $142.6M | $139.6M | $365.8M | $202.8M | $496.2M | $206.9M | $-1.38B |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $0 | $3.0M | $0 | — | — | — | — | — |
| Net Cash from Financing Activities | $180.6M | $42.1M | $30.0K | $1.5M | $36.2M | $-80.4M | $23.4M | $852.0M |
| Net Change in Cash | $-29.1M | $9.0M | $-53.0M | $63.0M | $-173.7M | $102.6M | $-98.5M | $190.1M |
| Free Cash Flow | $-208.7M | $-177.2M | $-193.5M | $-309.7M | $-427.6M | $-320.5M | $-355.0M | $704.0M |